+

WO2008133192A1 - Fused imidazole compound and use thereof - Google Patents

Fused imidazole compound and use thereof Download PDF

Info

Publication number
WO2008133192A1
WO2008133192A1 PCT/JP2008/057566 JP2008057566W WO2008133192A1 WO 2008133192 A1 WO2008133192 A1 WO 2008133192A1 JP 2008057566 W JP2008057566 W JP 2008057566W WO 2008133192 A1 WO2008133192 A1 WO 2008133192A1
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
nitrogen
oxide
containing heterocyclic
imidazole compound
Prior art date
Application number
PCT/JP2008/057566
Other languages
French (fr)
Japanese (ja)
Inventor
Seiji Miwatashi
Akira Kaieda
Masashi Takahashi
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of WO2008133192A1 publication Critical patent/WO2008133192A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed is a compound represented by the formula (I) below or a salt thereof. The compound is useful as a p38 MAPK inhibitor and/or a TNF-α production inhibitor. (In the formula, Xa, Xb and Xc may be the same or different and each represents an optionally substituted CH or a nitrogen atom, and either one of them represents a nitrogen atom; Xd represents an optionally substituted CH; Ra represents an optionally substituted phenyl or an optionally substituted heterocyclic group; Rb represents a hydrogen atom; Rc represents an optionally substituted nitrogen-containing heterocyclic N-oxide, an N-(optionally substituted nitrogen-containing heterocyclic N-oxide-C1-6-alkyl)amino or an optionally substituted nitrogen-containing heterocyclic N-oxide-carbonylamino-C1-6- alkyl.)
PCT/JP2008/057566 2007-04-19 2008-04-18 Fused imidazole compound and use thereof WO2008133192A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-111032 2007-04-19
JP2007111032 2007-04-19

Publications (1)

Publication Number Publication Date
WO2008133192A1 true WO2008133192A1 (en) 2008-11-06

Family

ID=39925646

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/057566 WO2008133192A1 (en) 2007-04-19 2008-04-18 Fused imidazole compound and use thereof

Country Status (1)

Country Link
WO (1) WO2008133192A1 (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820665B2 (en) 2007-12-19 2010-10-26 Amgen Inc. Imidazopyridazine inhibitors of PI3 kinase for cancer treatment
US7928140B2 (en) 2007-08-02 2011-04-19 Amgen Inc. Benzothiazole PI3 kinase modulators for cancer treatment
JP2013521320A (en) * 2010-03-09 2013-06-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Imidazo [1,2-a] pyrazine derivatives and their use for the prevention or treatment of neurological, mental and metabolic disorders and diseases
US8716282B2 (en) 2009-10-30 2014-05-06 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors
US8729074B2 (en) 2009-03-20 2014-05-20 Amgen Inc. Inhibitors of PI3 kinase
JP2014518223A (en) * 2011-06-20 2014-07-28 アルツハイマーズ・インスティテュート・オブ・アメリカ・インコーポレイテッド Compounds and their therapeutic uses
JP2015513559A (en) * 2012-03-14 2015-05-14 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Substituted imidazopyridazine
WO2015086501A1 (en) * 2013-12-09 2015-06-18 Ucb Biopharma Sprl Imidazopyridazine derivatives as modulators of tnf activity
US9145419B2 (en) 2010-04-28 2015-09-29 Bristol-Myers Squibb Company Imidazopyridazinyl compounds
JP2016531126A (en) * 2013-08-23 2016-10-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング New bisamide pyridine
US9550784B2 (en) 2012-07-09 2017-01-24 Beerse Pharmaceutica NV Inhibitors of phosphodiesterase 10 enzyme
US9669035B2 (en) 2012-06-26 2017-06-06 Janssen Pharmaceutica Nv Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl-[1,2,4]triazolo-[4,3-A]]quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological of metabolic disorders
JP2018522869A (en) * 2015-06-29 2018-08-16 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Polycyclic amide derivatives as CDK9 inhibitors
US10604523B2 (en) 2011-06-27 2020-03-31 Janssen Pharmaceutica Nv 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
WO2023247552A1 (en) 2022-06-21 2023-12-28 Syngenta Crop Protection Ag Microbiocidal bicyclic heterocyclic carboxamide derivatives
EP4096657A4 (en) * 2020-01-29 2024-07-10 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07503017A (en) * 1992-01-13 1995-03-30 スミスクライン・ビーチャム・コーポレイション Imidazole derivatives and their use as cytokine inhibitors
JP2003513977A (en) * 1999-11-10 2003-04-15 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Substituted 2-aryl-3- (heteroaryl) -imidazo [1,2-α] pyrimidines and related pharmaceutical compositions and methods
WO2005066177A1 (en) * 2003-12-31 2005-07-21 Schering-Plough Ltd. Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives
JP2006502164A (en) * 2002-09-06 2006-01-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド Imidazopyridine and its production and use
WO2006070943A1 (en) * 2004-12-28 2006-07-06 Takeda Pharmaceutical Company Limited Condensed imidazole compound and use thereof
JP2006519249A (en) * 2003-03-04 2006-08-24 ファイザー・プロダクツ・インク Novel condensed heteroaromatic compounds as transforming growth factor (TGF) inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07503017A (en) * 1992-01-13 1995-03-30 スミスクライン・ビーチャム・コーポレイション Imidazole derivatives and their use as cytokine inhibitors
JP2003513977A (en) * 1999-11-10 2003-04-15 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Substituted 2-aryl-3- (heteroaryl) -imidazo [1,2-α] pyrimidines and related pharmaceutical compositions and methods
JP2006502164A (en) * 2002-09-06 2006-01-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド Imidazopyridine and its production and use
JP2006519249A (en) * 2003-03-04 2006-08-24 ファイザー・プロダクツ・インク Novel condensed heteroaromatic compounds as transforming growth factor (TGF) inhibitors
WO2005066177A1 (en) * 2003-12-31 2005-07-21 Schering-Plough Ltd. Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives
WO2006070943A1 (en) * 2004-12-28 2006-07-06 Takeda Pharmaceutical Company Limited Condensed imidazole compound and use thereof

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7928140B2 (en) 2007-08-02 2011-04-19 Amgen Inc. Benzothiazole PI3 kinase modulators for cancer treatment
US7820665B2 (en) 2007-12-19 2010-10-26 Amgen Inc. Imidazopyridazine inhibitors of PI3 kinase for cancer treatment
US8729074B2 (en) 2009-03-20 2014-05-20 Amgen Inc. Inhibitors of PI3 kinase
US8716282B2 (en) 2009-10-30 2014-05-06 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors
US8859543B2 (en) 2010-03-09 2014-10-14 Janssen Pharmaceutica Nv Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases
JP2013521320A (en) * 2010-03-09 2013-06-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Imidazo [1,2-a] pyrazine derivatives and their use for the prevention or treatment of neurological, mental and metabolic disorders and diseases
US9145419B2 (en) 2010-04-28 2015-09-29 Bristol-Myers Squibb Company Imidazopyridazinyl compounds
JP2014518223A (en) * 2011-06-20 2014-07-28 アルツハイマーズ・インスティテュート・オブ・アメリカ・インコーポレイテッド Compounds and their therapeutic uses
US10604523B2 (en) 2011-06-27 2020-03-31 Janssen Pharmaceutica Nv 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
JP2015513559A (en) * 2012-03-14 2015-05-14 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Substituted imidazopyridazine
US9669035B2 (en) 2012-06-26 2017-06-06 Janssen Pharmaceutica Nv Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl-[1,2,4]triazolo-[4,3-A]]quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological of metabolic disorders
US9550784B2 (en) 2012-07-09 2017-01-24 Beerse Pharmaceutica NV Inhibitors of phosphodiesterase 10 enzyme
JP2016531126A (en) * 2013-08-23 2016-10-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング New bisamide pyridine
CN105814061A (en) * 2013-12-09 2016-07-27 Ucb生物制药私人有限公司 Imidazopyridazine derivatives as modulators of TNF activity
JP2016539975A (en) * 2013-12-09 2016-12-22 ユーシービー バイオファルマ エスピーアールエル Imidazopyridazine derivatives as modulators of TNF activity
US9873703B2 (en) 2013-12-09 2018-01-23 Ucb Biopharma Sprl Imidazopyridazine derivatives as modulators of TNF activity
RU2679609C1 (en) * 2013-12-09 2019-02-12 Юсб Байофарма Спрл Imidazopyridazine derivatives as modulators of tnf activity
WO2015086501A1 (en) * 2013-12-09 2015-06-18 Ucb Biopharma Sprl Imidazopyridazine derivatives as modulators of tnf activity
JP2018522869A (en) * 2015-06-29 2018-08-16 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Polycyclic amide derivatives as CDK9 inhibitors
JP6997627B2 (en) 2015-06-29 2022-01-17 アストラゼネカ・アクチエボラーグ Polycyclic amide derivative as a CDK9 inhibitor
EP4096657A4 (en) * 2020-01-29 2024-07-10 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
WO2023247552A1 (en) 2022-06-21 2023-12-28 Syngenta Crop Protection Ag Microbiocidal bicyclic heterocyclic carboxamide derivatives

Similar Documents

Publication Publication Date Title
WO2008133192A1 (en) Fused imidazole compound and use thereof
NO20070731L (en) Heterocyclic Compounds.
MX2009010824A (en) Heterocyclic hydrazide compound and pesticidal use of the same.
NZ601489A (en) Cyclic amine compound and acaricide
NO20075987L (en) Bicyclic derivatives as p38 kinase inhibitors
MX2010001773A (en) Method for preparing 5-haloalkyl-4,5-dihydroisoxazole derivatives.
NO20082561L (en) New coupled pyrrole derivatives
NO20053647L (en) Pyrazolopyridinderivater
PH12012501711A1 (en) [5,6] heterocyclic compound
TW200745028A (en) Novel sulphonylpyrroles
MX2007005933A (en) Acetamide compounds as fungicides.
WO2009028629A1 (en) Heterocyclic compound and use thereof
TW200612947A (en) Organic compounds
TW200745027A (en) Novel sulphonylpyrroles
DK1888063T3 (en) Antimycotic agents
NO20082209L (en) Homo and heterocyclic compounds useful as CETP inhibitors
WO2008057775A3 (en) Heterocyclic amide compounds useful as kinase inhibitors
ATE553106T1 (en) HETEROARYLPYRROLOPYRIDINONES AS KINASE INHIBITORS
MX2007005932A (en) 1-alkynyl-2-aryloxyalkylamides and their use as fungicides.
NO330968B1 (en) New Process for the Synthesis of (1S) -4,5-Dimethoxy-1- (methylaminomethyl) -benzocyclobutane and Addition Salts thereof, and Use in the Synthesis of Ivabradine and Addition Salts thereof with a Pharmaceutically Acceptable Acid
NO20082118L (en) Heterocyclic CETP Inhibitors
MX2010009276A (en) Pyrrolopyrimidinecarboxamides.
WO2007099171A3 (en) Bicyclo-pyrazoles active as kinase inhibitors
TW200619206A (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
TW200600499A (en) Novel amido-substituted hydroxy-6-phenylphenanthridines

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08740621

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: JP

122 Ep: pct application non-entry in european phase

Ref document number: 08740621

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载